Capsugel ICSE/CPHI Booth #8F06
Expanded Finished Product Manufacturing Facilities Ready for Increased Licaps® Production
MORRISTOWN, NJ and BORNEM, BELGIUM, October 11, 2012 – A global surveyi of decision-makers in the pharmaceutical industry published this week reveals a technology void in innovative dosage solutions. There is a clear need for innovative delivery technologies that ensure product integrity, increased bioavailability and reduced production-to-market lead time. Capsugel’s novel Fusion Technology for its Licaps capsules aims to fill this gap and set a new standard for liquid and semi-solid lipid based capsules by providing a dosage solution that can be used to meet the needs across a spectrum of challenging compounds. The company showcased its Licaps Fusion Technology this week at ICSE/CPHI 2012 taking place in Madrid.
“We continuously make innovations in our technologies so that we find new and better ways to help customers deliver effective, high quality products,” said Keith Hutchison, PhD, Senior Vice President of R&D at Capsugel. “Our improved Licaps Fusion Technology has been applied to products which received regulatory approval for use in clinical trials as well as products that are now commercially available. Our technology continues to exceed customer expectations.”
The recent completion of Capsugel’s state-of-the-art pharmaceutical manufacturing facility in the United States makes available additional capacity for the production of Licaps products, adding to existing sites in France and Japan to meet customer needs. The Licaps product manufacturing facility in Greenwood, SC now meets ISO 8 clean room environment standards and its quality systems support all cGMP requirements.
HOW IT WORKS
The Licaps Fusion Technology ensures that the two pieces of the capsules are hermetically sealed together, resulting in a perfectly tight, one-piece capsule. Licaps capsules are gelatin or HPMC hard capsules exclusively designed to optimize liquid filling and sealing.
ABOUT CAPSUGEL Capsugel is a global leader in innovative dosage forms and solutions for the healthcare industry. Offering a comprehensive array of products and services, from hard gelatin, liquid-filled, and vegetarian capsules, to innovative R&D product development services, Capsugel is at the forefront of drug delivery innovation providing support to customers from formulation to final production. For more information about Capsugel, visit www.capsugel.com.
For media inquiries, contact Catherine Lehmann, Marketing Manager at +33 3 89 20 58 46 or Alyssa Augustine, Director of Communications at +1 860 389 0868. Global Industry Survey, Nice Insights 2012
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance